Prostate cancer: Genomic drivers of resistance to AR therapies

被引：6
|
作者：
Kelsey R.
机构：
来源：
Nature Reviews Urology | 2018年 / 15卷 / 4期
关键词：
D O I：
10.1038/nrurol.2018.18
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：202 / 202
相关论文
共 50 条
  • [31] Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer
    Chetta, Paolo
    Zadra, Giorgia
    CANCER DRUG RESISTANCE, 2021, 4 (01) : 143 - 162
  • [32] Genomic landscape of acquired resistance to targeted therapies in metastatic colorectal cancer (mCRC).
    Harrold, Emily
    Keane, Fergus
    Sinopoli, Jenna Cohen
    Diaz, Luis A.
    Cercek, Andrea
    Yaeger, Rona
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 190 - 190
  • [33] Genomic profiling to overcome resistance to molecularly targeted therapies in metastatic colorectal cancer
    Strickler, John H.
    CANCER SCIENCE, 2023, 114 : 1522 - 1522
  • [34] Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted Therapies
    Hirata, Junichiro
    Hara, Takuto
    Jimbo, Naoe
    Ueki, Hideto
    Okamura, Yasuyoshi
    Bando, Yukari
    Suzuki, Kotaro
    Terakawa, Tomoaki
    Teishima, Jun
    Chiba, Koji
    Miyake, Hideaki
    ANTICANCER RESEARCH, 2025, 45 (03) : 1137 - 1147
  • [35] Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer
    Kwan, Edmond M.
    Wyatt, Alexander W.
    PROSTATE, 2022, 82 : S25 - S36
  • [36] Drivers of Radioresistance in Prostate Cancer
    King, Liam
    Bernaitis, Nijole
    Christie, David
    Chess-Williams, Russ
    Sellers, Donna
    McDermott, Catherine
    Dare, Wendy
    Anoopkumar-Dukie, Shailendra
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (19)
  • [37] Drivers of neuroendocrine prostate cancer
    Pinto, Filipe
    Reis, Rui Manuel
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S551 - S553
  • [38] Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.
    Scher, Howard I.
    Graf, Ryon
    Louw, Jessica
    Jendrisak, Adam
    Johnson, Ann
    Greene, Stephanie
    Rodriguez, Angel
    Schreiber, Nicole A.
    McLaughlin, Brigit
    Dugan, Lyndsey
    Fleisher, Martin
    Lee, Jerry
    Wang, Yipeng
    Marrinucci, Dena C.
    Landers, Mark
    Dittamore, Ryan Vance
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [39] Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer
    Lombard, Alan P.
    Liu, Liangren
    Cucchiara, Vito
    Liu, Chengfei
    Armstrong, Cameron M.
    Zhao, Ruining
    Yang, Joy C.
    Lou, Wei
    Evans, Christopher P.
    Gao, Allen C.
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (10) : 2197 - 2205
  • [40] Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer
    Zhang, Tian
    Karsh, Lawrence I.
    Nissenblatt, Michael J.
    Canfield, Steven E.
    CLINICAL GENITOURINARY CANCER, 2020, 18 (01) : 1 - 10
12345